Next Article in Journal
Aberrant Signaling Pathways in Glioma
Next Article in Special Issue
Novel Antibody-Based Proteins for Cancer Immunotherapy
Previous Article in Journal
Inflammation-Related Carcinogenesis and Prevention in Esophageal Adenocarcinoma Using Rat Duodenoesophageal Reflux Models
Previous Article in Special Issue
C-type Lectin Receptors for Tumor Eradication: Future Directions
Cancers 2011, 3(3), 3225-3241; doi:10.3390/cancers3033225
Review

Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans

1
, 1
, 1
, 1
, 1
, 1
, 2
 and 1,*
Received: 7 July 2011; in revised form: 2 August 2011 / Accepted: 3 August 2011 / Published: 10 August 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [500 KB, uploaded 10 August 2011]   |   Browse Figures
Abstract: DNA vaccination exploits a relatively simple and flexible technique to generate an immune response against microbial and tumor-associated antigens (TAAs). Its effectiveness is enhanced by the application of an electrical shock in the area of plasmid injection (electroporation). In our studies we exploited a sophisticated electroporation device approved for clinical use (Cliniporator, IGEA, Carpi, Italy). As the target antigen is an additional factor that dramatically modulates the efficacy of a vaccine, we selected ErbB2 receptor as a target since it is an ideal oncoantigen. It is overexpressed on the cell membrane by several carcinomas for which it plays an essential role in driving their progression. Most oncoantigens are self-tolerated molecules. To circumvent immune tolerance we generated two plasmids (RHuT and HuRT) coding for chimeric rat/human ErbB2 proteins. Their immunogenicity was compared in wild type mice naturally tolerant for mouse ErbB2, and in transgenic mice that are also tolerant for rat or human ErbB2. In several of these mice, RHuT and HuRT elicited a stronger anti-tumor response than plasmids coding for fully human or fully rat ErbB2. The ability of heterologous moiety to blunt immune tolerance could be exploited to elicit a significant immune response in patients. A clinical trial to delay the recurrence of ErbB2+ carcinomas of the oral cavity, oropharynx and hypopharynx is awaiting the approval of the Italian authorities.
Keywords: ErbB2; DNA vaccines; oncoantigens ErbB2; DNA vaccines; oncoantigens
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Quaglino, E.; Riccardo, F.; Macagno, M.; Bandini, S.; Cojoca, R.; Ercole, E.; Amici, A.; Cavallo, F. Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers 2011, 3, 3225-3241.

AMA Style

Quaglino E, Riccardo F, Macagno M, Bandini S, Cojoca R, Ercole E, Amici A, Cavallo F. Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers. 2011; 3(3):3225-3241.

Chicago/Turabian Style

Quaglino, Elena; Riccardo, Federica; Macagno, Marco; Bandini, Silvio; Cojoca, Rodica; Ercole, Elisabetta; Amici, Augusto; Cavallo, Federica. 2011. "Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans." Cancers 3, no. 3: 3225-3241.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert